- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
MYL
Mylan Stock May Fall Further After Hitting 52-Week Lows
Mylan stock is getting smashed after its fourth-quarter earnings results and full-year outlook. MYL stock could still go lower, though.
All Signals Are Positive for Buying Abbott Laboratories
Abbott is about to report another quarter to cap 2018's strong annual performance. ABT stock also offers a dividend for income investors.
Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow
Mylan stock jumped ahead following quarterly earnings that impressed investors. Management will continue doing better than expected.
5 Top Stock Trades for Wednesday: AMD’s Teaming Up With Amazon?
Earnings set to the tone for Toyota, CVS Health, Eli Lilly and Mylan as our top stock trades. But midterms will set the tone for the week.
Mylan Stock Is Soaring as Q3 Earnings Double, Top Expectations
Mylan stock (MYL) is soaring more than 7% after hours Monday as the. company's third-quarter earnings doubled and beat Wall Street estimates.
EpiPen News: FDA Extends Expiration Dates Due to Shortage
In the latest EpiPen news, the Food and Drug Administration (FDA) has extended the expiration dates of the allergy medication due to a shortage of EpiPens.
EpiPen Shortage 2018: 13 Things for Parents to Know
An EpiPen shortage has parents worried as the school season starts back up across the U.S., but there are other options.
After Disappointing Q2 Numbers, Mylan Stock Isn’t Terribly Exciting
MYL stock has been stuck in a downtrend for three-plus years, and nothing about second-quarter numbers imply that this downtrend is ending soon.
Mylan Stock Looks Cheap, but Don’t Overlook These Risks
Thinking about buying Mylan stock? These are the four risks that you need to understand before taking the plunge
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
Mylan NV Stock Up Despite Q1 Earnings and Revenue Miss
Mylan NV (MYL) stock was up on Wednesday following the release of its earnings report for the first quarter of the year.
Mylan NV Still Undervalued Despite Unveiling of New Products
MYL stock's forward P/E multiples don't reflect the growth potential for the Mylan NV. EpiPen demand and biosimilars will soon give the company a revenue lift.
Mylan NV Could Be Closer to a Breakout Than Most Traders Realize
Once all the Mylan headlines start to sink in, investor perspective could change. That would then move MYL stock that hasn't gone anywhere since February.
Revance Therapeutics Inc Is Set to Shake Up the Botox Market
RVNC has an edge with its formulation of Botox: it lasts longer. Given the little innovation in the botulinim toxin market, Revance has a real chance to succeed.
Expect a Slow and Steady Climb Ahead for Mylan NV
Negative public perception peaked for Mylan NV last year, but that's now history. With strong, positive cash flow in 2018 and new products lined up for MYL, value investors should take another look at Mylan stock.
Mylan Stock is One Stumble Away From a Big Technical Pullback
Thinking about buying Mylan stock? You may not want to just yet. It's toying with a support line that, if it snaps, could open the selling floodgates.